Predictors of Recurrent Laboratory-Confirmed Symptomatic SARS-CoV-2 Infections in a Cohort of Healthcare Workers
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Dahal, S.; Banda, J.M.; Bento, A.I.; Mizumoto, K.; Chowell, G. Characterizing all-cause excess mortality patterns during COVID-19 pandemic in Mexico. BMC Infect. Dis. 2021, 21, 432. [Google Scholar] [CrossRef] [PubMed]
- Palacio-Mejia, L.S.; Hernandez-Avila, J.E.; Hernandez-Avila, M.; Dyer-Leal, D.; Barranco, A.; Quezada-Sanchez, A.D.; Alvarez-Aceves, M.; Cortes-Alcala, R.; Fernandez-Wheatley, J.L.; Ordonez-Hernandez, I.; et al. Leading causes of excess mortality in Mexico during the COVID-19 pandemic 2020–2021: A death certificates study in a middle-income country. Lancet Reg. Health Am. 2022, 13, 100303. [Google Scholar] [CrossRef] [PubMed]
- Petras, M. Highly Effective Naturally Acquired Protection Against COVID-19 Persists for at Least 1 Year: A Meta-Analysis. J. Am. Med. Dir. Assoc. 2021, 22, 2263–2265. [Google Scholar] [CrossRef]
- Flacco, M.E.; Acuti Martellucci, C.; Baccolini, V.; De Vito, C.; Renzi, E.; Villari, P.; Manzoli, L. Risk of reinfection and disease after SARS-CoV-2 primary infection: Meta-analysis. Eur. J. Clin. Investig. 2022, 52, e13845. [Google Scholar] [CrossRef]
- Murillo-Zamora, E.; Trujillo, X.; Huerta, M.; Rios-Silva, M.; Aguilar-Sollano, F.; Mendoza-Cano, O. Symptomatic SARS-COV-2 reinfection: Healthcare workers and immunosuppressed individuals at high risk. BMC Infect. Dis. 2021, 21, 923. [Google Scholar] [CrossRef]
- Ramos, W.; Guerrero, N.; Napanga-Saldana, E.O.; Medina, J.; Loayza, M.; De La Cruz-Vargas, J.A.; Vargas, M.; Ordonez, L.; Seclen-Ubillus, Y.; Alvarez-Antonio, C.; et al. Hospitalization, death, and probable reinfection in Peruvian healthcare workers infected with SARS-CoV-2: A national retrospective cohort study. Hum. Resour. Health 2022, 20, 86. [Google Scholar] [CrossRef]
- Guedes, A.R.; Oliveira, M.S.; Tavares, B.M.; Luna-Muschi, A.; Lazari, C.D.S.; Montal, A.C.; de Faria, E.; Maia, F.L.; Barboza, A.D.S.; Leme, M.D.; et al. Reinfection rate in a cohort of healthcare workers over 2 years of the COVID-19 pandemic. Sci. Rep. 2023, 13, 712. [Google Scholar] [CrossRef]
- Lopez Bernal, J.; Andrews, N.; Gower, C.; Gallagher, E.; Simmons, R.; Thelwall, S.; Stowe, J.; Tessier, E.; Groves, N.; Dabrera, G.; et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N. Engl. J. Med. 2021, 385, 585–594. [Google Scholar] [CrossRef]
- Hernandez-Suarez, C.; Murillo-Zamora, E. Waning immunity to SARS-CoV-2 following vaccination or infection. Front. Med. 2022, 9, 972083. [Google Scholar] [CrossRef]
- Feikin, D.R.; Higdon, M.M.; Abu-Raddad, L.J.; Andrews, N.; Araos, R.; Goldberg, Y.; Groome, M.J.; Huppert, A.; O’Brien, K.L.; Smith, P.G.; et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression. Lancet 2022, 399, 924–944. [Google Scholar] [CrossRef]
- Chemaitelly, H.; Abu-Raddad, L.J. Waning effectiveness of COVID-19 vaccines. Lancet 2022, 399, 771–773. [Google Scholar] [CrossRef] [PubMed]
- Piazza, M.F.; Amicizia, D.; Marchini, F.; Astengo, M.; Grammatico, F.; Battaglini, A.; Sticchi, C.; Paganino, C.; Lavieri, R.; Andreoli, G.B.; et al. Who Is at Higher Risk of SARS-CoV-2 Reinfection? Results from a Northern Region of Italy. Vaccines 2022, 10, 1885. [Google Scholar] [CrossRef] [PubMed]
- Chemaitelly, H.; Nagelkerke, N.; Ayoub, H.H.; Coyle, P.; Tang, P.; Yassine, H.M.; Al-Khatib, H.A.; Smatti, M.K.; Hasan, M.R.; Al-Kanaani, Z.; et al. Duration of immune protection of SARS-CoV-2 natural infection against reinfection. J. Travel. Med. 2022, 29, taac109. [Google Scholar] [CrossRef] [PubMed]
- Swift, M.D.; Hainy, C.M.; Sampathkumar, P.; Breeher, L.E. Multiple SARS-CoV-2 Reinfections: A Case Series of Thrice-Infected Individuals. Mayo. Clin. Proc. 2022, 97, 1021–1023. [Google Scholar] [CrossRef] [PubMed]
- Bastard, J.; Taisne, B.; Figoni, J.; Mailles, A.; Durand, J.; Fayad, M.; Josset, L.; Maisa, A.; van der Werf, S.; Parent du Chatelet, I.; et al. Impact of the Omicron variant on SARS-CoV-2 reinfections in France, March 2021 to February 2022. Euro. Surveill. 2022, 27, 2200247. [Google Scholar] [CrossRef]
- Ruff, J.; Zhang, Y.; Kappel, M.; Rathi, S.; Watkins, K.; Zhang, L.; Lockett, C. Rapid Increase in Suspected SARS-CoV-2 Reinfections, Clark County, Nevada, USA, December 2021. Emerg. Infect. Dis. 2022, 28, 1977–1981. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention. Reinfections and COVID-19 (Updated on 9 September 2022). Available online: https://www.cdc.gov/coronavirus/2019-ncov/your-health/reinfection.html (accessed on 24 January 2023).
- Nguyen, N.N.; Houhamdi, L.; Hoang, V.T.; Delerce, J.; Delorme, L.; Colson, P.; Brouqui, P.; Fournier, P.E.; Raoult, D.; Gautret, P. SARS-CoV-2 reinfection and COVID-19 severity. Emerg Microbes Infect 2022, 11, 894–901. [Google Scholar] [CrossRef]
- General Directorate of Epidemiology of Mexico. Standardized Guidelines for Epidemiological and Laboratory Surveillance of Viral Respiratory Disease. Available online: https://www.gob.mx/salud/documentos/lineamiento-estandarizado-para-la-vigilancia-epidemiologica-y-por-laboratorio-de-la-enfermedad-respiratoria-viral (accessed on 27 December 2022). (In Spanish).
- Murillo-Zamora, E.; Sanchez-Pina, R.A.; Trujillo, X.; Huerta, M.; Rios-Silva, M.; Mendoza-Cano, O. Independent risk factors of COVID-19 pneumonia in vaccinated Mexican adults. Int. J. Infect. Dis. 2022, 118, 244–246. [Google Scholar] [CrossRef]
- Wolfe, K.; Sirota, M.; Clarke, A.D.F. Age differences in COVID-19 risk-taking, and the relationship with risk attitude and numerical ability. R. Soc. Open Sci. 2021, 8, 201445. [Google Scholar] [CrossRef]
- Monaco, M.G.L.; Spiteri, G.; Caliskan, G.; Lotti, V.; Carta, A.; Gibellini, D.; Verlato, G.; Porru, S. SARS-CoV-2 and Its Variants in Thrice-Infected Health Workers: A Case Series from an Italian University Hospital. Viruses 2022, 14, 2536. [Google Scholar] [CrossRef]
- Kaim, A.; Saban, M. Are we suffering from the Peltzman effect? Risk perception among recovered and vaccinated people during the COVID-19 pandemic in Israel. Public Health 2022, 209, 19–22. [Google Scholar] [CrossRef] [PubMed]
- Juyal, D.; Pal, S.; Thaledi, S.; Pandey, H.C. COVID-19: The vaccination drive in India and the Peltzman effect. J. Fam. Med. Prim. Care 2021, 10, 3945–3947. [Google Scholar] [CrossRef] [PubMed]
- Henk, K.; Rosing, F.; Wolff, F.; Frenzel, S.B.; van Dick, R.; Erkens, V.A.; Hausser, J.A.; Mojzisch, A.; Boer, D. An examination and extension of the Peltzman effect during the Covid-19 pandemic. Curr. Res. Ecol. Soc. Psychol. 2023, 4, 100091. [Google Scholar] [CrossRef]
- Tsai, C.I.; Zeng, Y. Risky but alluring: Severe COVID-19 pandemic influence increases risk taking. J. Exp. Psychol. Appl. 2021, 27, 679–694. [Google Scholar] [CrossRef] [PubMed]
- Ochoa-Hein, E.; Leal-Moran, P.E.; Nava-Guzman, K.A.; Vargas-Fernandez, A.T.; Vargas-Fernandez, J.F.; Diaz-Rodriguez, F.; Rayas-Bernal, J.A.; Gonzalez-Gonzalez, R.; Vazquez-Gonzalez, P.; Huertas-Jimenez, M.A.; et al. Significant Rise in SARS-CoV-2 Reinfection Rate in Vaccinated Hospital Workers during the Omicron Wave: A Prospective Cohort Study. Rev. Investig. Clin. 2022, 74, 175–180. [Google Scholar] [CrossRef]
- Ramonfaur, D.; Hinojosa-Gonzalez, D.E.; Rodriguez-Gomez, G.P.; Iruegas-Nunez, D.A.; Flores-Villalba, E. COVID-19 vaccine hesitancy and acceptance in Mexico: A web-based nationwide survey. Rev. Panam. Salud. Publica. 2021, 45, e133. [Google Scholar] [CrossRef]
- Mistry, P.; Barmania, F.; Mellet, J.; Peta, K.; Strydom, A.; Viljoen, I.M.; James, W.; Gordon, S.; Pepper, M.S. SARS-CoV-2 Variants, Vaccines, and Host Immunity. Front. Immunol. 2021, 12, 809244. [Google Scholar] [CrossRef]
- Ayoubkhani, D.; Bermingham, C.; Pouwels, K.B.; Glickman, M.; Nafilyan, V.; Zaccardi, F.; Khunti, K.; Alwan, N.A.; Walker, A.S. Trajectory of long covid symptoms after covid-19 vaccination: Community based cohort study. BMJ 2022, 377, e069676. [Google Scholar] [CrossRef]
- Juvonen, J.; Lessard, L.M.; Kline, N.G.; Graham, S. Young Adult Adaptability to the Social Challenges of the COVID-19 Pandemic: The Protective Role of Friendships. J. Youth Adolesc. 2022, 51, 585–597. [Google Scholar] [CrossRef]
- Seyed Alinaghi, S.; Afsahi, A.M.; Mohsseni Pour, M.; Behnezhad, F.; Salehi, M.A.; Barzegary, A.; Mirzapour, P.; Mehraeen, E.; Dadras, O. Late Complications of COVID-19; a Systematic Review of Current Evidence. Arch. Acad. Emerg. Med. 2021, 9, e14. [Google Scholar] [CrossRef]
- Nordgren, J.; Sharma, S.; Olsson, H.; Jamtberg, M.; Falkeborn, T.; Svensson, L.; Hagbom, M. SARS-CoV-2 rapid antigen test: High sensitivity to detect infectious virus. J. Clin. Virol. 2021, 140, 104846. [Google Scholar] [CrossRef] [PubMed]
- Chi, W.Y.; Li, Y.D.; Huang, H.C.; Chan, T.E.H.; Chow, S.Y.; Su, J.H.; Ferrall, L.; Hung, C.F.; Wu, T.C. COVID-19 vaccine update: Vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J. Biomed. Sci. 2022, 29, 82. [Google Scholar] [CrossRef] [PubMed]
Characteristic | Overall (n = 1700) | Number of COVID-19 Episodes | p | ||||
---|---|---|---|---|---|---|---|
One or Two (n = 1686) | Three (n = 14) | ||||||
Gender | |||||||
Female | 1079 | (63.5) | 1069 | (63.4) | 10 | (71.4) | 0.535 |
Male | 621 | (36.5) | 617 | (36.6) | 4 | (28.6) | |
Age (years) a | 37.1 ± 8.1 | 37.1 ± 8.1 | 30.8 ± 5.6 | 0.004 | |||
Age group | |||||||
<20 | 2 | (0.1) | 2 | (0.1) | 0 | (0) | 0.007 |
20–29 | 300 | (17.7) | 292 | (17.3) | 8 | (57.2) | |
30–39 | 826 | (48.6) | 821 | (48.7) | 5 | (35.7) | |
40–49 | 440 | (25.8) | 439 | (26.0) | 1 | (7.1) | |
50–59 | 119 | (7.0) | 119 | (7.1) | 0 | (0) | |
60+ | 13 | (0.8) | 13 | (0.8) | 0 | (0) | |
COVID-19 vaccination status b | |||||||
Unvaccinated | 1545 | (90.9) | 1539 | (91.3) | 6 | (42.9) | <0.001 |
Vaccinated | 155 | (9.1) | 147 | (8.7) | 8 | (57.1) | |
Severity of the first COVID-19 episode c | |||||||
Mild | 1682 | (98.9) | 1669 | (99.0) | 13 | (92.9) | 0.026 |
Severe | 18 | (1.1) | 17 | (1.0) | 1 | (7.1) | |
Activity in healthcare services | |||||||
Other | 1064 | (62.6) | 1055 | (62.6) | 9 | (64.3) | 0.192 |
Nurse | 378 | (22.2) | 373 | (22.1) | 5 | (35.7) | |
Physician | 258 | (15.2) | 258 | (15.3) | 0 | (0) | |
Personal history of: | |||||||
Obesity (BMI 30 or above) | |||||||
No | 1451 | (85.4) | 1441 | (85.5) | 10 | (71.4) | 0.139 |
Yes | 249 | (14.6) | 245 | (14.5) | 4 | (28.6) | |
Arterial hypertension | |||||||
No | 1572 | (92.5) | 1559 | (92.5) | 13 | (92.9) | 0.956 |
Yes | 128 | (7.5) | 127 | (7.5) | 1 | (7.1) | |
Type 2 diabetes mellitus | |||||||
No | 1632 | (96.0) | 1618 | (96.0) | 14 | (100) | 0.443 |
Yes | 68 | (4.0) | 68 | (4.0) | 0 | (0) | |
Asthma | |||||||
No | 1647 | (96.9) | 1633 | (96.9) | 14 | (100) | 0.500 |
Yes | 53 | (3.1) | 53 | (3.1) | 0 | (0) |
Characteristic | RR (95% CI), p | |||
---|---|---|---|---|
Bivariate Analysis | Multiple Analysis | |||
Gender | ||||
Female | Ref. | Ref. | ||
Male | 0.99 (0.98–1.01) | 0.535 | 0.99 (0.98–1.01) | 0.878 |
Age (years) | 0.98 (0.97–0.99) | 0.004 | 0.98 (0.97–0.99) | 0.008 |
COVID-19 vaccination status b | ||||
Unvaccinated | Ref. | Ref. | ||
Vaccinated | 1.05 (1.02–1.06) | <0.001 | 1.05 (1.03–1.06) | <0.001 |
Obesity (BMI 30 or above) | ||||
No | Ref. | Ref. | ||
Yes | 1.01 (0.99–1.03) | 0.139 | 1.01 (0.99–1.02) | 0.187 |
Severity of the first COVID-19 episode c | ||||
Mild | Ref. | Ref. | ||
Severe | 1.05 (1.01–1.09) | 0.025 | 1.05 (1.01–1.10) | 0.020 |
Activity in healthcare services | ||||
Other | Ref. | Ref. | ||
Nurse | 1.00 (0.99–1.02) | 0.378 | 1.01 (0.99–1.02) | 0.434 |
Physician | 0.99 (0.98–1.00) | 0.177 | 0.99 (0.98–1.01) | 0.467 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Trujillo, X.; Mendoza-Cano, O.; Ríos-Silva, M.; Huerta, M.; Guzmán-Esquivel, J.; Benites-Godínez, V.; Lugo-Radillo, A.; Bricio-Barrios, J.A.; Cárdenas-Rojas, M.I.; Ríos-Bracamontes, E.F.; et al. Predictors of Recurrent Laboratory-Confirmed Symptomatic SARS-CoV-2 Infections in a Cohort of Healthcare Workers. Vaccines 2023, 11, 626. https://doi.org/10.3390/vaccines11030626
Trujillo X, Mendoza-Cano O, Ríos-Silva M, Huerta M, Guzmán-Esquivel J, Benites-Godínez V, Lugo-Radillo A, Bricio-Barrios JA, Cárdenas-Rojas MI, Ríos-Bracamontes EF, et al. Predictors of Recurrent Laboratory-Confirmed Symptomatic SARS-CoV-2 Infections in a Cohort of Healthcare Workers. Vaccines. 2023; 11(3):626. https://doi.org/10.3390/vaccines11030626
Chicago/Turabian StyleTrujillo, Xóchitl, Oliver Mendoza-Cano, Mónica Ríos-Silva, Miguel Huerta, José Guzmán-Esquivel, Verónica Benites-Godínez, Agustin Lugo-Radillo, Jaime Alberto Bricio-Barrios, Martha I. Cárdenas-Rojas, Eder Fernando Ríos-Bracamontes, and et al. 2023. "Predictors of Recurrent Laboratory-Confirmed Symptomatic SARS-CoV-2 Infections in a Cohort of Healthcare Workers" Vaccines 11, no. 3: 626. https://doi.org/10.3390/vaccines11030626
APA StyleTrujillo, X., Mendoza-Cano, O., Ríos-Silva, M., Huerta, M., Guzmán-Esquivel, J., Benites-Godínez, V., Lugo-Radillo, A., Bricio-Barrios, J. A., Cárdenas-Rojas, M. I., Ríos-Bracamontes, E. F., Ortega-Macías, V. M., Ruiz-Montes de Oca, V., & Murillo-Zamora, E. (2023). Predictors of Recurrent Laboratory-Confirmed Symptomatic SARS-CoV-2 Infections in a Cohort of Healthcare Workers. Vaccines, 11(3), 626. https://doi.org/10.3390/vaccines11030626